Archive - May 2018
Opioid Withdrawal Treatment: First Nonopioid Drug To Manage Symptoms Approved By FDA
AstraZeneca and Emulate advance ‘organs-on-chips’ research partnership
Aerie Pharmaceuticals Submits NDA to FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
FDA Approves Lucemyra (lofexidine hydrochloride) as the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms
GE Increases Cell Culture Media Production Capacity
IPEC-Americas Acquires Global Excipient Event
Catalent to Develop Biosimilars for Valerius Biopharma
Cambrex Reports Expansions at its High Point, NC Facility